Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Related Articles
Blood Global Hematology | American Society of Hematology
Jorge Cortes, MD director of the Georgia Cancer Center at Augusta University and inaugural Editor-in-Chief of Blood Global Hematology, shares his vision for the journal…
Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis
Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.
Intraoperative Fluid Balance and Perioperative Complications in Ovarian Cancer Surgery
Annals of Surgical Oncology – Fluid overload and hypovolemia promote postoperative complications in patients undergoing cytoreductive surgery for ovarian cancer. In the present study, postoperative…
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS
Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.
FcRn and Myasthenia Gravis
The role of neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG) and treatment options
American Society of Hematology: building a comprehensive minority recruitment and retention professional program
Abstract. In 2003, the Institute of Medicine noted the need to improve workforce diversity. The American Society of Hematology (ASH) responded by developin
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Key PointsIptacopan monotherapy is cost saving for anti-C5–treated patients with suboptimal response vs continuation of C5 inhibitors.Improved quality of l
Novel Therapies and Combinations Lead the Way in Women’s Cancers in 2024
Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.
Precision Medicine in AML: An Abundance of Options | Blood Cancers Today
Experts delve deeper into the evolving treatment landscape, focusing on the transformative role of targeted therapies.
